Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Dermatology Updates: From Allergic Reactions to Microbiome Therapies
This week's dermatology update covers allergic contact dermatitis triggers, HPV vaccination guidelines, chronic urticaria insights, new treatments for atopic dermatitis, and the evolving understanding of skin microbiome interactions.
Bibliography
1. Allergic contact dermatitis caused by cosmetic products.
Authors: González-Muñoz P, Conde-Salazar L, Vañó-Galván S
Journal: Actas dermo-sifiliograficas, 2014 Nov
PMID: 24656778
DOI: 10.1016/j.ad.2013.12.018
2. Human Papillomavirus Vaccination.
Authors: Markowitz LE, Unger ER
Journal: The New England journal of medicine, 2023 May 11
PMID: 37163625
DOI: 10.1056/NEJMcp2108502
3. Chronic Spontaneous Urticaria: The Devil's Itch.
Authors: Saini SS, Kaplan AP
Journal: The journal of allergy and clinical immunology. In practice, 2018 Jul-Aug
PMID: 30033911
DOI: 10.1016/j.jaip.2018.04.013
4. European S2k Guideline on Chronic Pruritus.
Authors: Weisshaar E, Szepietowski JC, Dalgard FJ, et al.
Journal: Acta dermato-venereologica, 2019 Apr 1
PMID: 30931482
DOI: 10.2340/00015555-3164
5. Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
Authors: Zhao Y, Zhang L, Wu L, et al.
Journal: The Journal of dermatological treatment, 2026 Dec
PMID: 42403221
DOI: 10.1080/09546634.2026.2670890
6. Human Papillomavirus Vaccination.
Authors: Markowitz LE, Unger ER
Journal: The New England journal of medicine, 2023 May 11
PMID: 37163625
DOI: 10.1056/NEJMcp2108502
7. The Human Skin Microbiome in Selected Cutaneous Diseases.
Authors: Carmona-Cruz S, Orozco-Covarrubias L, Sáez-de-Ocariz M
Journal: Frontiers in cellular and infection microbiology, 2022
PMID: 35321316
DOI: 10.3389/fcimb.2022.834135
8. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial.
Authors: King B, Ehst B, Foley P, et al.
Journal: The British journal of dermatology, 2026 Jul 17
PMID: 41905775
DOI: 10.1093/bjd/ljag109
Authors: González-Muñoz P, Conde-Salazar L, Vañó-Galván S
Journal: Actas dermo-sifiliograficas, 2014 Nov
PMID: 24656778
DOI: 10.1016/j.ad.2013.12.018
2. Human Papillomavirus Vaccination.
Authors: Markowitz LE, Unger ER
Journal: The New England journal of medicine, 2023 May 11
PMID: 37163625
DOI: 10.1056/NEJMcp2108502
3. Chronic Spontaneous Urticaria: The Devil's Itch.
Authors: Saini SS, Kaplan AP
Journal: The journal of allergy and clinical immunology. In practice, 2018 Jul-Aug
PMID: 30033911
DOI: 10.1016/j.jaip.2018.04.013
4. European S2k Guideline on Chronic Pruritus.
Authors: Weisshaar E, Szepietowski JC, Dalgard FJ, et al.
Journal: Acta dermato-venereologica, 2019 Apr 1
PMID: 30931482
DOI: 10.2340/00015555-3164
5. Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
Authors: Zhao Y, Zhang L, Wu L, et al.
Journal: The Journal of dermatological treatment, 2026 Dec
PMID: 42403221
DOI: 10.1080/09546634.2026.2670890
6. Human Papillomavirus Vaccination.
Authors: Markowitz LE, Unger ER
Journal: The New England journal of medicine, 2023 May 11
PMID: 37163625
DOI: 10.1056/NEJMcp2108502
7. The Human Skin Microbiome in Selected Cutaneous Diseases.
Authors: Carmona-Cruz S, Orozco-Covarrubias L, Sáez-de-Ocariz M
Journal: Frontiers in cellular and infection microbiology, 2022
PMID: 35321316
DOI: 10.3389/fcimb.2022.834135
8. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial.
Authors: King B, Ehst B, Foley P, et al.
Journal: The British journal of dermatology, 2026 Jul 17
PMID: 41905775
DOI: 10.1093/bjd/ljag109
